Experimental therapies reported in the literature for plantar fibromatosis include radiotherapy, extracorporeal shock wave therapy, and antiestrogen therapy.5 Although very effective for Dupuytren contractures and Peyronie disease, collagenase C. histolyticum was not effective in treating plantar fibromatosis in this patient. This lack of success is likely attributable to the anatomical properties unique to this disease process in the plantar region (which typically includes a nodule instead of a cord or plaque) rather than specific to this patient. However, additional studies are needed to further evaluate the effectiveness of collagenase C. histolyticum as a treatment modality for plantar fibromatosis.
The author has no financial interest to declare in relation to the content of this article.
Ziyad S. Hammoudeh, M.D.
4201 St. Antoine, 6C-UHC
Detroit, Mich. 48201
1. Zgonis T, Jolly GP, Polyzois V, Kanuck DM, Stamatis ED. Plantar fibromatosis. Clin Podiatr Med Surg. 2005;22:11–18
2. van der Veer WM, Hamburg SM, de Gast A, Niessen FB. Recurrence of plantar fibromatosis after plantar fasciectomy: Single-center long-term results. Plast Reconstr Surg. 2008;122:486–491
3. Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: A new nonsurgical treatment for Dupuytren’s disease. J Hand Surg Am. 2010;35:2027–2038.e1
4. Gelbard M, Goldstein I, Hellstrom WJ, et al. Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol. 2013;190:199–207
5. Veith NT, Tschernig T, Histing T, Madry H. Plantar fibromatosis: Topical review. Foot Ankle Int. 2013;34:1742–1746
Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:
- Text—maximum of 500 words (not including references)
- References—maximum of five
- Authors—no more than five
- Figures/Tables—no more than two figures and/or one table
Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.
We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.